Viridian Therapeutics Inc Stock News

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of no...

Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Thyroid Eye Disease, outperforming Tepezza in early stages and targeting both active and chronic TED. VRDN-001 achieved significant efficacy in the Thrive trial, meeting all primary and secondary endpoints with strong proptosis and diplopia resolution rates, and was well-tolerated. Financially, Viridian has ...

Three small biotech stocks that I have covered lately have shown significant upward movement recently due to positive news. The stocks are experiencing what I call the 'Big Mo,' indicating strong momentum that could lead to additional upward movement. We follow up on these three small biotech/biopharma names and bring followers up to date on the recent positive news flow around them in the para...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferr...

Viridian Therapeutics, Inc. reported that the primary endpoint was met for the phase 3 THRIVE study, using veligrotug for the treatment of patients with active thyroid eye disease. Data release for THRIVE-2 study, using veligrotug for the treatment of patients with chronic thyroid eye disease, expected end of 2024. It is expected that the 7 major thyroid eye disease markets will reach $4.13 bil...

Viridian Therapeutics Inc (NASDAQ:VRDN) stock is up 11.1% to trade at $15.75 today, and earlier traded as high as $16.35, after the biotech company's eye disorder treatment met the main goal of a late-stage study.

Viridian Therapeutics stock jumped Tuesday after unveiling promising results for its Amgen-rivaling eye disease treatment.

Viridian Therapeutics said on Tuesday its experimental drug to treat patients with thyroid eye disease significantly reduced bulging of the eye in a late-stage study.